DongKook Life Science Co

DongKook Life Science Co EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of DongKook Life Science Co (303810.KQ) as of Nov 5, 2026 is 13.05 B KRW. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 12.75 B KRW — a change of 2.31% (higher).

EBITDA

13.05 BKRW

YoY

2.31%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of DongKook Life Science Co is 2025 13.05 B KRW. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of DongKook Life Science Co was 2024 12.75 B KRW. It decreases by 2.31% higher compared to the previous year.

The DongKook Life Science Co EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2022
6.83 B KRW
Jan 1, 2023
9.46 B KRW
Jan 1, 2024
12.75 B KRW
Jan 1, 2025
13.05 B KRW
The DongKook Life Science Co EBITDA history
YEAREBITDAYoY
13.05 BKRW+2.31%
12.75 BKRW+34.78%
9.46 BKRW+38.52%
6.83 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

DongKook Life Science Co Stock analysis

What does DongKook Life Science Co do? DongKook Life Science Co Ltd generates revenue through the production and sale of contrast agents, including X-ray contrast agents and magnetic resonance imaging (MRI) contrast agents, alongside the distribution and sale of medical equipment and medical devices. The company serves healthcare providers and medical institutions that require diagnostic imaging solutions, focusing on the Korean market with its Seoul headquarters. Its primary products are contrast agents for medical imaging procedures, which are essential for diagnostics in hospitals and clinics. The firm's business model centers on supplying specialized medical products to the healthcare sector, leveraging its expertise in contrast agent manufacturing. By offering both imaging contrast agents and complementary medical equipment, DongKook Life Science targets hospitals and diagnostic centers seeking comprehensive imaging solutions. The company's operations are rooted in the production of medical imaging tools that support diagnostic procedures in Korea. DongKook Life Science Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about DongKook Life Science Co stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of DongKook Life Science Co is 13.05 B KRW in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of DongKook Life Science Co changed from 12.75 B KRW to 13.05 B KRW, representing a 2.31% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) DongKook Life Science Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s DongKook Life Science Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — DongKook Life Science Co

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — DongKook Life Science Co